Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells

Anticancer Res. 2004 Nov-Dec;24(6):3961-4.

Abstract

Background: VEGF (Vascular Endothelial Growth Factor) is a key factor of angiogenesis and high tissue VEGF levels are related to a poor prognosis in breast cancer.

Materials and methods: By semi-quantitative RT-PCR, we determined the relative expressions of VEGF mRNA in MCF-7 (both ER-alpha+ and ER-beta+ (mainly ER-alpha+), PR+, bcl-2+, EGFR-) and MB-MDA-231 (only ER-beta+, PR-, EGFR-) breast cancer cells which were treated with estrogen, tamoxifen and EGF (Epidermal Growth Factor).

Results: In MCF-7 cell lines, estrogen induced the expression of VEGF mRNA while tamoxifen reduced its expression. Estrogen and tamoxifen did not confer any significant effect on MB-MDA-231 cells and EGF showed no significant effect on MCF-7 or MB-MDA-231.

Conclusion: Reduced VEGF mRNA expression of MCF-7 cells treated with tamoxifen may be related to the antagonistic effect of tamoxifen on ER-positive breast cancer, and this antagonistic effect may be related to ER-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • Densitometry
  • Epidermal Growth Factor / pharmacology*
  • Estradiol / pharmacology*
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • RNA, Messenger / biosynthesis
  • RNA, Messenger / genetics
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tamoxifen / pharmacology*
  • Transcription, Genetic / drug effects*
  • Vascular Endothelial Growth Factor A / biosynthesis*
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • RNA, Messenger
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Tamoxifen
  • Estradiol
  • Epidermal Growth Factor